Investor and Media Contact:SMP CommunicationsSusan Pietropaolospietropaolo@bccpartners.com(201) 923-2049
MENLO PARK, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the fourth quarter and fiscal year (FY) ended September 30, 2016 on Monday, November 21, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress. Conference Call and Webcast Details Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 17537774. The conference call also will be available via a live audio webcast which may be accessed here, or by visiting "Events & Presentations" in the Investors section of the Company's website at www.coriumgroup.com. The webcast will be archived on the Corium website for two weeks following the presentation. About Corium Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor ®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that has recently completed Phase 3 trials, and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com. Corplex™ and MicroCor ® are registered trademarks of Corium International, Inc.